C
Charles A. Dinarello
Researcher at University of Colorado Denver
Publications - 1073
Citations - 152254
Charles A. Dinarello is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Interleukin & Cytokine. The author has an hindex of 190, co-authored 1058 publications receiving 139668 citations. Previous affiliations of Charles A. Dinarello include University of Guadalajara & Pennsylvania State University.
Papers
More filters
Journal Article
IL-1 induction-capacity of defined lipopolysaccharide partial structures.
Harald Loppnow,Helmut Brade,I. Dürrbaum,Charles A. Dinarello,Shoichi Kusumoto,Ernst Th. Rietschel,Hans-Dieter Flad +6 more
TL;DR: It is concluded that lipid A is the main portion of LPS responsible for induction of IL-1, and that specific activation- and-or binding-mechanisms are involved in stimulation of cells with LPS and/or lipid A.
Journal ArticleDOI
Osmotic regulation of cytokine synthesis in vitro
TL;DR: These studies suggest that IL-1 and osmotic shock utilize the same mitogen-activated protein kinase for signal transduction and IL-8 synthesis.
Journal ArticleDOI
Why not treat human cancer with interleukin-1 blockade?
TL;DR: Clinical trials of interleukin-1 blockade should be initiated, particularly as an add-on therapy of patients receiving antiangiogenesis-based therapies, given the availability of three therapeutic agents for limiting IL-1 activity, the safety of blockingIL-1, and the clear benefit of blocking IL- 1 activity in animal models of metastasis and angiogenesis.
Journal ArticleDOI
Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation
Irena Kaplanov,Yaron Carmi,Rachel Kornetsky,Avishai Shemesh,Galina V. Shurin,Michael R. Shurin,Charles A. Dinarello,Elena Voronov,Ron N. Apte +8 more
TL;DR: Microenvironmental IL-1β is defined as a master cytokine in tumor progression using a model of orthotopically introduced 4T1 breast cancer cells and the combination of anti–IL-1 β plus anti–PD-1 abrogated the tumors completely.
Journal ArticleDOI
Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome
Karin Mazodier,Valérie Marin,Daniela Novick,Catherine Farnarier,Stéphane Robitail,Nicolas Schleinitz,Véronique Veit,Pascale Paul,Menachem Rubinstein,Charles A. Dinarello,Jean-Robert Harlé,Gilles Kaplanski +11 more
TL;DR: It is concluded that a severe IL-18/IL-18BP imbalance results in Th-1 lymphocyte and macrophage activation, which escapes control by NK-cell cytotoxicity and may allow for secondary HPS in patients with underlying diseases.